<!DOCTYPE html>
<html lang="en-us">
    <head>
        

        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1">
        <title>Combined Immunogenomic and Immunopeptidomic Analyses Identified Biologically Relevant Immune Signatures and Novel Immunotherapy Targets in Osteosarcoma</title>
        
        <style>

    html body {
        font-family: 'Raleway', sans-serif;
        background-color: white;
    }

    :root {
        --accent: red;
        --border-width:  5px ;
    }

</style>


<link rel="stylesheet" href="http://example.com/css/main.css">





<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Raleway">


 <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/default.min.css"> 


<link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha384-BVYiiSIFeK1dGmJRAkycuHAHRg32OmUcww7on3RYdg4Va+PmSTsz/K68vbdEjh4u" crossorigin="anonymous">


<link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha384-wvfXpqpZZVQGK6TAh5PVlGOfQNHSoD2xbE+QkPxCAFlNEevoEH3Sl0sibVcOQVnN" crossorigin="anonymous">
 

    <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js"></script>
    
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/go.min.js"></script>
    
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/haskell.min.js"></script>
    
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/kotlin.min.js"></script>
    
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/scala.min.js"></script>
    
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/swift.min.js"></script>
    
    <script>hljs.initHighlightingOnLoad();</script>






<script src="https://ajax.googleapis.com/ajax/libs/jquery/3.4.1/jquery.min.js"></script>


<script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha384-Tc5IQib027qvyjSMfHjOMaLkfuWVxZxUPnCJA7l2mCWNIpG9mGCD8wGNIcPD7Txa" crossorigin="anonymous"></script>


<script>$(document).on('click', function() { $('.collapse').collapse('hide'); })</script>
 <meta name="generator" content="Hugo 0.72.0" />
        

        

        
            <script type="text/javascript" async src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
        

        

    </head>

    <body>
        

        <nav class="navbar navbar-default navbar-fixed-top">
            <div class="container">
                <div class="navbar-header">
                    <a class="navbar-brand visible-xs" href="#">Combined Immunogenomic and Immunopeptidomic Analyses Identified Biologically Relevant Immune Signatures and Novel Immunotherapy Targets in Osteosarcoma</a>
                    <button class="navbar-toggle" data-target=".navbar-collapse" data-toggle="collapse">
                        <span class="icon-bar"></span>
                        <span class="icon-bar"></span>
                        <span class="icon-bar"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse">
                    
                        <ul class="nav navbar-nav">
                            
                                <li><a href="/">Home</a></li>
                            
                                <li><a href="/about/">About</a></li>
                            
                                <li><a href="/abstract/">Abstracts</a></li>
                            
                                <li><a href="/tags/">PI Index</a></li>
                            
                        </ul>
                    
                    
                        <ul class="nav navbar-nav navbar-right">
                            
                                <li class="navbar-icon"><a href="mailto:me@example.com"><i class="fa fa-envelope-o"></i></a></li>
                            
                                <li class="navbar-icon"><a href="https://github.com/username/"><i class="fa fa-github"></i></a></li>
                            
                                <li class="navbar-icon"><a href="https://twitter.com/username/"><i class="fa fa-twitter"></i></a></li>
                            
                                <li class="navbar-icon"><a href="https://www.linkedin.com/in/username/"><i class="fa fa-linkedin"></i></a></li>
                            
                                <li class="navbar-icon"><a href="https://www.stackoverflow.com/username/"><i class="fa fa-stack-overflow"></i></a></li>
                            
                        </ul>
                    
                </div>
            </div>
        </nav>


<main>

    <div>
        <h2>Combined Immunogenomic and Immunopeptidomic Analyses Identified Biologically Relevant Immune Signatures and Novel Immunotherapy Targets in Osteosarcoma</h2>
        <h5></h5>
        
<a href="http://example.com/tags/javed-khan"><kbd class="item-tag">Javed Khan</kbd></a>


    </div>

    <div align="start" class="content"><p>David Milewski, Jun S. Wei, Sivasish Sindiri, Andrew Brohl, Young Song, Xinyu Wen, Andy Qi, Udayan Guha, and Javed Khan.</p>
<p>Background: Osteosarcoma is an aggressive bone tumor that is one of the leading causes of cancer-related death in the pediatric population. Several phase I clinical trials have reported occasional clinical responses to immune checkpoint inhibitors in osteosarcoma patients. The key feature of immunotherapy involves T cell recognition of peptides from abnormal proteins (tumor-associated antigens; TAAs) presented by MHC class I of tumor cells which stimulates specific anti-tumor cytotoxicity. Currently, the role of immunotherapy for osteosarcoma remains to be determined.  Furthermore, little is known about the TAAs presented by osteosarcoma tumors which can be targeted by T cells. The goal of this work is to perform a deep immunogenomic and proteomic profiling of osteosarcoma tumors as the basis for developing effective immune-based therapy for osteosarcoma.</p>
<p>Methods: Osteosarcoma tumors and cell lines were subjected to whole transcriptomes analysis. Intratumoral T cell receptor sequences were identified using MiXCR and VDJtools from the RNA-seq data. Immune signatures were scored in each tumor sample using single-sample GSEA. MHC class I bound peptides were isolated by immunoprecipitation of MHC class I complex, acid elution of bound peptides, and identification using LC-MS/MS. Healthy donor T cells were transduced with a reported TCR targeting a  PRAME peptide and co-cultured with osteosarcoma cells to evaluate cytotoxicity.</p>
<p>Results: Gene expression profiling of extracranial pediatric solid tumors identified high T cell infiltration in osteosarcoma patient tumors. CD8+ T cell infiltration were associated with favorable outcome among osteosarcoma patients, suggesting the presence of an underlying endogenous T cell response against osteosarcoma tumors. In addition, we identified TAAs which are frequently overexpressed in osteosarcoma but display low/absent expression in normal tissues. To determine if any of these TAAs are presented on MHC class I in osteosarcoma, we performed large scale immunoprecipitation of MHC class I complexes, peptide isolation and identification by LC-MS/MS.  We found that the immunopeptidome of osteosarcoma is rich in TAAs, including cancer germline antigens (CGAs), which may be immunogenic for T cells.  Furthermore, we identified multiple peptides from PRAME, one of the most commonly overexpressed TAAs across pediatric solid tumors, highlighting it as a prime candidate target for T cell therapy. In a proof-of-concept experiment, we demonstrate effective T cell cytotoxicity against osteosarcoma using a TCR specific for the PRAME-MHC class I peptide identified by mass spectrometry.</p>
<p>Conclusions: Osteosarcoma tumors have prognostic high CD8+ T cell infiltration, expression of targetable TAAs, and presentation of tumor associated peptides on MHC class I complex which can be effectively targeted with engineered T cells. These data warrant a broad evaluation of the treatment of osteosarcoma using immunotherapy.</p>
<ul>
<li>Submitter: David Milewski (Postdoc or fellow)</li>
<li>Supervisor: Javed Khan</li>
<li>email: <a href="mailto:david.milewski@nih.gov">david.milewski@nih.gov</a></li>
</ul>
</div>

</main>

        <footer>
            <p class="copyright text-muted">Â© All rights reserved. Powered by <a href="https://gohugo.io">Hugo</a> and <a href="https://github.com/calintat/minimal">Minimal</a>.</p>
        </footer>

        

        
    </body>

</html>

